Literature DB >> 10233988

Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice.

E Cantin1, B Tanamachi, H Openshaw, J Mann, K Clarke.   

Abstract

Mouse strains with null mutations in the gamma interferon gene (Ifng) or the gamma interferon receptor gene (Ifngr) have been engineered. The use of these strains as animal models of viral and bacterial infections has enhanced our understanding of the role of gamma interferon (IFN-gamma) in the host immune response. However, direct comparisons between Ifng-/- (GKO) and Ifngr-/- (RGKO) mice have been problematic because previously available strains of these mice have had different genetic backgrounds (i.e., C57BL/6 and BALB/c for GKO mice and 129/Sv//Ev for RGKO mice). To enable direct comparison of herpes simplex virus type 1 (HSV-1) infections in GKO and RGKO mice, we introduced the IFN-gamma null mutation into the 129/Sv//Ev background. We report that, after HSV-1 inoculation, mortality was significantly greater in RGKO mice than in GKO mice (38 versus 23%, P = 0.0001). Similarly, the mortality from vaccinia virus challenge was significantly greater in RGKO mice than in GKO mice. With differences in genetic background excluded as a confounding issue, these results are consistent with the existence of an alternative ligand(s) for the IFN-gamma receptor that is also capable of mediating protection against viral challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233988      PMCID: PMC112570     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice.

Authors: 
Journal:  Neuron       Date:  1997-10       Impact factor: 17.173

2.  Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice.

Authors:  E M Simpson; C C Linder; E E Sargent; M T Davisson; L E Mobraaten; J J Sharp
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

3.  Pathological changes in the spleens of gamma interferon receptor-deficient mice infected with murine gammaherpesvirus: a role for CD8 T cells.

Authors:  B M Dutia; C J Clarke; D J Allen; A A Nash
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 4.  Cytokines and immunity to viral infections.

Authors:  I A Ramshaw; A J Ramsay; G Karupiah; M S Rolph; S Mahalingam; J C Ruby
Journal:  Immunol Rev       Date:  1997-10       Impact factor: 12.988

5.  Role for gamma interferon in control of herpes simplex virus type 1 reactivation.

Authors:  E Cantin; B Tanamachi; H Openshaw
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes.

Authors:  B Wang; I André; A Gonzalez; J D Katz; M Aguet; C Benoist; D Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

7.  Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.

Authors:  B Balasa; C Deng; J Lee; L M Bradley; D K Dalton; P Christadoss; N Sarvetnick
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

Review 8.  Immune defence in mice lacking type I and/or type II interferon receptors.

Authors:  M F van den Broek; U Müller; S Huang; R M Zinkernagel; M Aguet
Journal:  Immunol Rev       Date:  1995-12       Impact factor: 12.988

9.  Interferon gamma gene expression in sensory neurons: evidence for autocrine gene regulation.

Authors:  H Neumann; H Schmidt; E Wilharm; L Behrens; H Wekerle
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

10.  Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations.

Authors:  L K Selin; S M Varga; I C Wong; R M Welsh
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  49 in total

1.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  The case for immunomodulatory approaches in treating HSV encephalitis.

Authors:  Chandran Ramakrishna; Harry Openshaw; Edouard M Cantin
Journal:  Future Virol       Date:  2013-03-01       Impact factor: 1.831

3.  Resistance to vaccinia virus is less dependent on TNF under conditions of heterologous immunity.

Authors:  Siwei Nie; Markus Cornberg; Liisa K Selin
Journal:  J Immunol       Date:  2009-10-21       Impact factor: 5.422

4.  Interferon-gamma, macrophages, and virus spread after HSV-1 injection.

Authors:  Heather M Cathcart; Mei Zheng; Jason J Covar; Yi Liu; Robert Podolsky; Sally S Atherton
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-07       Impact factor: 4.799

5.  Microglia and a functional type I IFN pathway are required to counter HSV-1-driven brain lateral ventricle enlargement and encephalitis.

Authors:  Christopher D Conrady; Min Zheng; Nico van Rooijen; Douglas A Drevets; Derek Royer; Anthony Alleman; Daniel J J Carr
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

6.  Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice.

Authors:  S C Whitman; P Ravisankar; H Elam; A Daugherty
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

7.  Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors.

Authors:  Gary D Luker; Julie L Prior; Jiling Song; Christina M Pica; David A Leib
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice.

Authors:  Patric Lundberg; Paula Welander; Harry Openshaw; Christina Nalbandian; Carl Edwards; Lyle Moldawer; Edouard Cantin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice.

Authors:  J Peltoniemi; E K Broberg; A Halenius; N Setala; J-P Eralinna; A A Salmi; M Roytta; V Hukkanen
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.